Sequence: STR-H16R8 (stearyl-(His)16-(Arg)8)
| Experiment Id | EXP001504 |
|---|---|
| Paper | Therapeutic potential of a cell penetrating peptide (CPP, NP1) mediated siRNA delivery: Evidence in |
| Peptide | NP1 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 6 µM |
| Rna Concentration | 100 nM |
| Mixing Ratio | MR 1/60 (siRNA/NP1; N/R≈60) |
| Formulation Format | noncovalent NP1/siRNA complex (nanoparticle) |
| Formulation Components | NP1 + Bcl-2 siRNA (electrostatic complex) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro (3D spheroid) |
| Cell Lines Or Primary Cells | HCT 116 3D tumour spheroids (hanging drop) |
| Animal Model | |
| Administration Route | |
| Output Type | Gene knockdown (qRT-PCR, 96 h); protein (western blot, 5 days) |
| Output Value | ~53% Bcl-2 mRNA knockdown; Bcl-2 protein suppressed vs control |
| Output Units | |
| Output Notes | In 3D spheroids, NP1-Bcl-2-siRNA induced ~53% mRNA knockdown (96 h). Western blot after 5 days showed significant Bcl-2 protein suppression (greater than Lipofectamine 2000). |
| Toxicity Notes | |
| Curation Notes |